3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Neoplasm Metastasis
3
Philadelphia Chromosome
2
Ovarian Neoplasms
2
Neoplasms
2
Myeloproliferative Disorders
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia
2
Sarcoma
1
Recurrence
1
Peritoneal Neoplasms
1
Neoplasm, Residual
1
Leukemia, Myeloid
1
Hematologic Diseases
1
Genital Neoplasms, Female
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Breast Neoplasms
1
Blast Crisis
1
Appendiceal Neoplasms
1
Interventions
Practice Guidelines as Topic
5
Standard of Care
4
Specimen Handling
3
Docetaxel
3
pertuzumab
2
Trastuzumab
2
Taxes
2
Paclitaxel
2
Minoxidil
2
Methods
2
Interviews as Topic
2
High-Energy Shock Waves
2
Educational Status
2
Early Intervention, Educational
2
Biopsy
2
trastuzumab biosimilar HLX02
1
Yoga
1
Transcutaneous Electric Nerve Stimulation
1
Radiation Dose Hypofractionation
1
Palliative Care
1
PF-05280014
1
Ontruzant
1
Ogivri
1
Nutrition Assessment
1
Mental Status and Dementia Tests
1
Magnetic Resonance Spectroscopy
1
Immunoglobulin G
1
Goserelin
1
Geriatric Assessment
1
Genetic Testing
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Anatomic Stage I Breast Cancer AJCC v8
×
nilotinib
×
90 days
×
Clear all
No trials found.